<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454361</url>
  </required_header>
  <id_info>
    <org_study_id>KBP7072-1-001</org_study_id>
    <nct_id>NCT02454361</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of KBP-7072</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the
      safety, tolerability and pharmacokinetics of a single dose of KBP-7072 following oral single
      ascending dose administration and with an open label food effect panel.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the
      safety, tolerability and pharmacokinetics of a single dose of KBP-7072 following oral single
      ascending dose administration and with an open label food effect panel.

      Part 1: A total of 40 subjects will be evaluated with 30 subjects randomized to receive
      active drug and 10 subjects randomized to receive placebo in a double-blind fashion (eight
      subjects in each dose cohort, six subjects randomized to active drug and two subjects
      randomized to placebo). 5 dose levels will be evaluated. Extensive PK samplings will be
      collected after dosing (pre-dose (within 30 min prior to dosing) and at 0.5, 1, 2, 4, 6, 10,
      12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hr post-dose).

      Part 2: A separate panel of 6 subjects will receive a single dose of KBP-7072 under fed
      conditions. The dose tested in Part 2 will be determined based on the safety, tolerability
      and PK data available from Part 1. Extensive PK samplings will be collected after dosing
      (pre-dose (within 45 min prior to dosing) and at 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 36, 48, 72,
      96, 120, 144, 168, 192, 216 and 240 hr post-dose).

      Safety assessments will include monitoring of adverse events (AEs), vital signs (blood
      pressure, pulse rate, respiratory rate and oral temperature), clinical laboratory findings,
      12-lead electrocardiograms (ECGs), and physical examination findings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability (i.e., number of participants with adverse events): predose and postdose</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) Time Frame: predose, 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hr post-dose</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) Time Frame: predose, 0.5, 1, 2, 4, 6, 10, 12, 18, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 hr post-dose among participants who have had food</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>KBP-7072 cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-7072 by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072 cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-7072 by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072 cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-7072 by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072 cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-7072 by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072 cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-7072 by mouth once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KBP-7072 Fed Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KBP-7072 by mouth once to the fed group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-7072</intervention_name>
    <description>KBP-7072</description>
    <arm_group_label>KBP-7072 cohort 1</arm_group_label>
    <arm_group_label>KBP-7072 cohort 2</arm_group_label>
    <arm_group_label>KBP-7072 cohort 3</arm_group_label>
    <arm_group_label>KBP-7072 cohort 4</arm_group_label>
    <arm_group_label>KBP-7072 cohort 5</arm_group_label>
    <arm_group_label>KBP-7072 Fed Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>KBP-7072 cohort 1</arm_group_label>
    <arm_group_label>KBP-7072 cohort 2</arm_group_label>
    <arm_group_label>KBP-7072 cohort 3</arm_group_label>
    <arm_group_label>KBP-7072 cohort 4</arm_group_label>
    <arm_group_label>KBP-7072 cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  males and surgically sterile or postmenopausal females

          -  aged between 18-45 years

          -  body mass index (BMI) 19 ≤ BMI ≤ 30 kg/m2,

          -  no significant medical history

          -  normal renal function

          -  good general health

        Exclusion Criteria:

          -  Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,
             endocrine, hematologic, psychiatric, renal, hepatic, pulmonary, neurologic,
             immunologic, lipid metabolism disorders, or drug hypersensitivity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KBP</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <last_update_submitted>December 28, 2015</last_update_submitted>
  <last_update_submitted_qc>December 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>KBP-7072</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

